In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer in 2010) for the treatment of FAP based on clinical trial data.
Gustav, Hereditary Prince of Sayn-Wittgenstein-Berleburg | Related | Denishawn School of Dancing and Related Arts | Clinical Orthopaedics and Related Research | United States House Appropriations Subcommittee on Transportation, Housing and Urban Development, and Related Agencies | RAR-related orphan receptor alpha | Peter, Hereditary Prince of Yugoslavia | Hereditary Prince of Sayn-Wittgenstein-Berleburg | Amyloidosis | State Earnings-Related Pension Scheme | Small ubiquitin-related modifier 1 | Performance-related pay | performance-related pay | ''Paying Homage to the Hereditary King in Front of Copenhagen Castle, 18 October 1660''
Wolfgang Heimbach | List of LGBT-related organizations | Hereditary spastic paraplegia | Hereditary Prince of Saxe-Coburg and Gotha | Hereditary Education Policy | Head-related transfer function | Guillaume, Hereditary Grand Duke of Luxembourg | Gang Related (soundtrack) | Cell division cycle 7-related protein kinase | amyloidosis | Alfred, Hereditary Prince of Saxe-Coburg and Gotha |
Alternatively, a European Medicines Agency approved drug Tafamidis or Vyndaqel now exists which stabilizes transthyretin tetramers comprising wild type and different mutant subunits against amyloidogenesis halting the progression of peripheral neuropathy and autonomic nervous system dysfunction.